TOXINS 2015

TOXINS 2015: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins
January 14-17, 2015  Lisbon, Portuga
l

www.neurotoxins.org/toxins-2015/

IAB Attendance:

Board of Directors: Dirk Dressler, MD, PhD

Parallel Track II (Clinical)
14:30 – 16:10 Application of BoNT for the Treatment of Cerebral Palsy
Chair: Ann Tilton (New Orleans, LA, USA)
14:30 – 14:55 Evidence-Based Review of Safety and Efficacy in Cerebral Palsy
Ann Tilton (New Orleans, LA, USA)
14:55 – 15:20 Optimizing Outcomes With Adjunctive Therapy
Anthony Ward (Stoke-on-Trent, UK)
15:20 – 15:45 Special Considerations: Dosing Limits and Reasons that Children Discontinue Therapy
Florian Heinen (Munich, Germany)
15:45 – 16:10 Managing Drooling in Cerebral Palsy
Steffen Berweck (Vogtareuth, Germany)
Parallel Track – Clinical (Workshop D)
14:30 – 16:00 Techniques for Localizing Muscles for BoNT Injection: Demonstration Workshop
Chair: Erle Lim (Singapore)
14:30 – 15:00 EMG
Marina de Koning-Tijssen (Groningen, Netherlands)
15:00 – 15:30 Ultrasound
Katharine Alter (Bethesda, MD, USA)
15:30 – 16:00 Other Techniques, Including Inspection, Palpation, Anatomic Landmarks
Erle Lim (Singapore)
16:00 – 16:30 Break
16:30 – 18:00 Treatment of Tremor With BoNT
Chair: Dirk Dressler (Hannover, Germany)
16:30 – 17:00 Approach to Hand Tremors
Seth Pullman (New York, NY, USA)
17:00 – 17:30 Head Tremor
Wolfgang Jost (Wiesbaden, Germany)
17:30 – 18:00 Voice Tremor
Robert Bastian (Downers Grove, IL, USA)
Parallel Track I (Clinical)
14:30 – 16:00 Clinical Pearls: Optimizing Outcomes in Blepharospasm and Hemifacial Spasm
Chair: Giovanni DeFazio (Bari, Italy)
14:30 – 15:00 Diagnosis of Blepharospasm: Are We There Yet?
Giovanni DeFazio (Bari, Italy)
15:00 – 15:30 Is There One Toxin/Dose That is Superior to Another for Blepharospasm/Hemifacial Spasm (HFS)?
Anna Rita Bentivoglio (Rome, Italy)
15:30 – 16:00 How to Inject for Optimal Outcome
Earl Consky (Toronto, Canada)
16:00 – 16:30 Break
16:30 – 17:00 Platform Session − Long-Term Studies of BoNT Efficacy, Safety, and Responsiveness
Chairs: Giovanni DeFazio (Bari, Italy) and Peter Moore (Liverpool, UK)
 16:30 – 16:40 Treatment Patterns and Patient Disposition in the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)
Cynthia Comella (Chicago, IL, USA)
 16:40 – 16:50 Efficacy of IncobotulinumtoxinA in Poststroke Upper Limb Spasticity: Results From a Large Multicenter 1-Year Noninterventional Study
Dirk Dressler (Hannover, Germany)
 16:50 – 17:00 Botulinum Toxin in Sialorrhea Is Safe and Effective in Long-Term Use
Martina Petracca (Rome, Italy)
17:00 – 18:30 Considerations When Botulinum Toxin Treatment Is Not Effective
Chair: Peter Moore (Liverpool, UK)
17:00 – 17:30 The Many Causes of Secondary Nonresponse
Cynthia Comella (Chicago, IL, USA)
17:30 – 18:00 Molecular Basis of Immunogenicity to Botulinum Neurotoxins
M. Zouhair Atassi (Houston, TX, USA)
18:00 – 18:30 Assessing Antibodies to Botulinum Toxin
Dirk Dressler (Hannover, Germany)

176. The ComCal to facilitate the communication between physicians and physiotherapists in botulinum neurotoxin therapy of spasticity

Toxicon, Volume 93, Supplement, January 2015, Page S55
Fereshte Adib Saberi, Heidrun M. Pickenbrock, Dirk Dressler

67. Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum neurotoxin therapy

Toxicon, Volume 93, Supplement, January 2015, Pages S21-S22
Dirk Dressler, Fereshte Adib Saberi

63. Botulinum neurotoxin therapy: reduction of injection site pain by pH normalization

Toxicon, Volume 93, Supplement, January 2015, Pages S20-S21
Dirk Dressler, Fereshte Adib Saberi, Hans Bigalke

68. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin)

Toxicon, Volume 93, Supplement, January 2015, Page S22
Dirk Dressler, Pawel Tacik, Fereshte Adib Saberi

64. Botulinum neurotoxin therapy of cervical dystonia: duration of therapeutic effects

Toxicon, Volume 93, Supplement, January 2015, Page S21
Dirk Dressler, Pawel Tacik, Fereshte Adib Saberi

65. Efficacy of incobotulinumtoxinA in poststroke upper limb spasticity: results from a large multicenter 1-year noninterventional study

Toxicon, Volume 93, Supplement, January 2015, Page S21
Dirk Dressler, Reinhard Rychlik, Nicole Schnur, Judith Lambert-Baumann

66. Mouse diaphragm assay confirms identical potency labeling for onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin)

Toxicon, Volume 93, Supplement, January 2015, Page S21
Dirk Dressler, Hans Bigalke

83. Use of concomitant therapies in real-life clinical management of patients with poststroke upper limb spasticity treated with botulinum toxin: German-Austrian subgroup of the ULIS II study

Toxicon, Volume 93, Supplement, January 2015, Page S26
Klemens Fheodoroff, Dirk Dressler, Hartwig Woldag, Peter Kossmehl, Gerhard Reichel

151. Botulinum neurotoxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures

Toxicon, Volume 93, Supplement, January 2015, Page S47
Lejla Paracka, Katja Kollewe, Dirk Dressler

100. Children are not little adults—dosage and development do matter

ToxiconVolume 93, SupplementJanuary 2015Pages S30-S31
Florian Heinen, Steffen Berweck, A. Sebastian Schroeder

24. Managing drooling in cerebral palsy

ToxiconVolume 93, SupplementJanuary 2015Page S9
Steffen Berweck, A. Sebastian Schroeder, Christine Jansen, Florian Heinen

Scroll to Top ↑

Hinweis zur Nutzung des Google reCAPTCHA
Die auf dieser Website eingesetzten Formulare beinhalten das unsichtbare reCAPTCHA zur Verhinderung von Spam.
Die Nutzung des unsichtbaren reCAPTCHA unterliegt der Datenschutzerklärung und den Nutzungsbedingungen von Google.